Alto Neuroscience (ANRO) News Today $3.89 +0.17 (+4.57%) (As of 12/20/2024 04:32 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Franklin Resources Inc. Purchases 595,673 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)Franklin Resources Inc. increased its position in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 95.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,220,712 shares of the company's stock afterDecember 21 at 4:46 AM | marketbeat.comAlto Neuroscience, Inc. (ANRO) Receives a Buy from JonesTradingDecember 17, 2024 | markets.businessinsider.comJones Trading Initiates Coverage of Alto Neuroscience (ANRO) with Buy RecommendationDecember 17, 2024 | msn.comBrokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) Target Price at $20.00December 16, 2024 | americanbankingnews.comAlto Neuroscience, Inc. (NYSE:ANRO) Short Interest UpdateAlto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) was the target of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 4,080,000 shares, a decrease of 12.4% from the November 15th total of 4,660,000 shares. Based on an average daily volume of 777,200 shares, the days-to-cover ratio is currently 5.2 days. Currently, 18.6% of the shares of the stock are sold short.December 15, 2024 | marketbeat.comAlto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and five have assigned a buy rating toDecember 13, 2024 | marketbeat.comAlto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of NeuropsychopharmacologyDecember 11, 2024 | finance.yahoo.comJennison Associates LLC Acquires 370,612 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)Jennison Associates LLC lifted its stake in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 80.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 832,290 shares of the company's stock after acquiring an additiNovember 23, 2024 | marketbeat.comFY2024 EPS Estimate for Alto Neuroscience Boosted by AnalystAlto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Stock analysts at William Blair increased their FY2024 EPS estimates for Alto Neuroscience in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Minter now forecasts that the company will post earnings per share ofNovember 18, 2024 | marketbeat.comFY2024 EPS Estimates for Alto Neuroscience Cut by WedbushAlto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Research analysts at Wedbush decreased their FY2024 EPS estimates for shares of Alto Neuroscience in a research note issued on Wednesday, November 13th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($2.60November 15, 2024 | marketbeat.comPotential Catalysts and Strategic Focus: Analyzing Alto Neuroscience’s Upcoming Trials and Precision Psychiatry ApproachNovember 14, 2024 | markets.businessinsider.comAlto Neuroscience price target lowered to $10 from $32 at StifelNovember 14, 2024 | markets.businessinsider.comAlto Neuroscience, Inc. (ANRO) Receives a Buy from TD CowenNovember 14, 2024 | markets.businessinsider.comAlto Neuroscience Strengthens Financial Position Amid Increased R&DNovember 14, 2024 | tipranks.comStifel Nicolaus Issues Pessimistic Forecast for Alto Neuroscience (NYSE:ANRO) Stock PriceStifel Nicolaus reduced their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday.November 13, 2024 | marketbeat.comAlto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 13, 2024 | finance.yahoo.comANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the FirmNovember 5, 2024 | globenewswire.comANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Alto Neuroscience, Inc. and Encourages Investors to Contact the FirmNovember 4, 2024 | businesswire.comANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the FirmNovember 3, 2024 | prnewswire.comANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the FirmOctober 30, 2024 | globenewswire.comAlto Neuroscience, Inc. (NYSE:ANRO) Sees Significant Increase in Short InterestAlto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 5,350,000 shares, a growth of 29.9% from the September 30th total of 4,120,000 shares. Based on an average daily trading volume, of 656,800 shares, the short-interest ratio is presently 8.1 days. Approximately 24.1% of the company's stock are sold short.October 28, 2024 | marketbeat.comWedbush Lowers Earnings Estimates for Alto NeuroscienceAlto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Research analysts at Wedbush reduced their Q1 2025 earnings estimates for Alto Neuroscience in a research note issued to investors on Wednesday, October 23rd. Wedbush analyst L. Chico now forecasts that the company will post earnings per share oOctober 28, 2024 | marketbeat.comFY2028 EPS Forecast for Alto Neuroscience Lowered by AnalystAlto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Equities researchers at William Blair decreased their FY2028 earnings estimates for Alto Neuroscience in a research report issued to clients and investors on Tuesday, October 22nd. William Blair analyst M. Minter now forecasts that the company wOctober 25, 2024 | marketbeat.comWedbush Downgrades Alto Neuroscience (ANRO)October 25, 2024 | msn.comRODMAN&RENSHAW Lowers Alto Neuroscience (NYSE:ANRO) to HoldRODMAN&RENSHAW downgraded shares of Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Wednesday.October 24, 2024 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Stock, Insider Trading ActivityOctober 24, 2024 | benzinga.comAlto Neuroscience falls -62.8%October 24, 2024 | markets.businessinsider.comAlto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have issuedOctober 24, 2024 | marketbeat.comAlto hits new low as depression drug flunks key testOctober 23, 2024 | finance.yahoo.comNeuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About PlatformOctober 23, 2024 | benzinga.comWedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readoutOctober 23, 2024 | markets.businessinsider.comAlto Neuroscience, Inc. (ANRO) Gets a Buy from Stifel NicolausOctober 23, 2024 | markets.businessinsider.comAlto Neuroscience stock crashes amid failed study and Wedbush downgradeOctober 23, 2024 | seekingalpha.comANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law FirmOctober 23, 2024 | prnewswire.comAlto Neuroscience Target of Unusually High Options Trading (NYSE:ANRO)Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 2,129 call options on the stock. This is an increase of approximately 21% compared to the typical daily volume of 1,755 call options.October 23, 2024 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Stock Rating Lowered by WedbushWedbush lowered shares of Alto Neuroscience from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $29.00 to $4.00 in a research report on Wednesday.October 23, 2024 | marketbeat.comAlto Neuroscience (NYSE:ANRO) Price Target Cut to $10.00 by Analysts at Robert W. BairdRobert W. Baird dropped their price target on Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating for the company in a research note on Wednesday.October 23, 2024 | marketbeat.comAlto Neuroscience falls 47% after announcing ALTO-100 did not meet endpointOctober 23, 2024 | markets.businessinsider.comAlto Neuroscience’s Phase 2b study of ALTO-100 did not meet primary endpointOctober 23, 2024 | markets.businessinsider.comAlto Neuroscience (NYSE:ANRO) Stock Price Up 1.6% - Here's What HappenedAlto Neuroscience (NYSE:ANRO) Shares Up 1.6% - Still a Buy?October 23, 2024 | marketbeat.comAlto Neuroscience Shares Plunge After ALTO-100 Study Misses Primary EndpointOctober 22, 2024 | marketwatch.comAlto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive DisorderOctober 22, 2024 | businesswire.comANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law FirmOctober 22, 2024 | businesswire.com2 Breakout Growth Stocks With 200% Upside PotentialOctober 19, 2024 | msn.comPoint72 Asset Management L.P. Trims Stake in Alto Neuroscience, Inc. (NYSE:ANRO)Point72 Asset Management L.P. trimmed its position in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 6.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,050,037 shares of the company's stock after selling 74,963 sharesOctober 1, 2024 | marketbeat.comAlto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of "Buy" by BrokeragesShares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have received a consensus rating of "Buy" from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month tSeptember 29, 2024 | marketbeat.comTD Asset Management Inc Takes $928,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO)TD Asset Management Inc bought a new position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 86,792 shares of the company's stock, valuSeptember 15, 2024 | marketbeat.comAnalysts Are Bullish on These NA Stocks: Alto Neuroscience, Inc. (ANRO), Rubrik, Inc. Class A (RBRK)September 11, 2024 | markets.businessinsider.comAlto Neuroscience Insiders Placed Bullish Bets Worth US$638.5kSeptember 11, 2024 | finance.yahoo.comBuy Rating Affirmed for Alto Neuroscience, Inc. Amid Promising ALTO-100 Clinical DevelopmentsSeptember 11, 2024 | markets.businessinsider.com Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << ANRO Media Mentions By Week ANRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANRO News Sentiment▼0.230.60▲Average Medical News Sentiment ANRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANRO Articles This Week▼52▲ANRO Articles Average Week Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies REGENXBIO News Today Alumis News Today Akebia Therapeutics News Today Cryoport News Today Procaps Group News Today Neurogene News Today biote News Today Voyager Therapeutics News Today Design Therapeutics News Today Contineum Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANRO) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANRO Stock Alerts